Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy
Grazia Arpino(University of Naples Federico II), Sabino De Placido, Antonello Accurso(University of Naples Federico II), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Carmine De Angelis(Baylor College of Medicine), Anna Crispo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Valeria Forestieri(University of Naples Federico II), Gennaro Limite(University of Naples Federico II), Mario Giuliano(Regione Campania), Bianca Maria Veneziani(Federico II University Hospital), Dario Bruzzese(University of Naples Federico II), Rossella Lauria, Stefania Cicala(University of Naples Federico II), Annamaria Colao(Federico II University Hospital), Giuseppe Buono(Federico II University Hospital), Simona Malgieri(University of Naples Federico II)
Cited by 49
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
|Clinical Endocrinology|2006|830
Guidelines for Acromegaly Management: An Update
|The Journal of Clinical Endocrinology & Metabolism|2009|763
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Complications of Cushing's syndrome: state of the art
|The Lancet Diabetes & Endocrinology|2016|602